IOVA Iovance Biotherapeutics, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
21:23
Sep 02
Sep 02
IOVA flagged as potential biotech acquisition target
Speaker identifies IOVA on TD Cowen acquisition candidate list, noting UAE delegation visit as potential M&A harbinger. Implies possible takeout but no direct position language or directional commitment stated.
LOW
19:07
Aug 30
Aug 30
IOVA upside from UAE deal and ESMO results.
Believes IOVA's current valuation reflects existing fundamentals; upside catalysts include UAE partnership benefits and ESMO data in October, suggesting a buy-into-catalyst long.
MED
18:36
Aug 30
Aug 30
Author reviews patient case studies on negative Signatera testing but does not state a position.
Author reviews patient case studies on negative Signatera testing but does not state a position or forward-looking trade call.
LOW
17:12
Aug 28
Aug 28
IOVA bet on cellular immunotherapy explosion
Take long exposure to IOVA as a cellular immunotherapy play; the author expects the field to explode with digital biology and personalized medicine and names IOVA as his specific bet. The reasoning is thematic and conviction-driven but thin on company-specific catalysts.
MED
16:21
Aug 28
Aug 28
Sovereign wealth interest may boost IOVA.
Buy IOVA on signs of sovereign wealth interest: UAE visited the company and is building Mubadala Bio, potentially targeting an oncology/cell-therapy platform.
MED
23:05
Aug 27
Aug 27
"IOVA reportedly seeking M&A instead of raise"
Speaker relays that IOVA may pursue M&A rather than a capital raise, referencing a potential strategic transaction without taking a directional stance.
LOW
20:06
Aug 27
Aug 27
IOVA named as no-brainer buy pick.
Answering a direct request for a no-brainer buy, the author names IOVA as a bullish pick; no specific company catalyst is provided.
MED
20:03
Aug 27
Aug 27
Author sarcastically defends IOVA's profitability and approved TIL drug against a parent claim.
Author sarcastically defends IOVA's profitability and approved TIL drug against a parent claim about RXRX losses, but makes no explicit forward-looking position call.
LOW
10:06
Aug 27
Aug 27
IOVA to appreciate on revenue, NSCLC data
Author believes IOVA will appreciate due to accelerating revenue growth and an upcoming NSCLC (non-small cell lung cancer) data catalyst, reinforcing a previously FDA-approved cure with high ORR for metastatic cancer.
MED
11:22
Aug 25
Aug 25
IOVA buyout optionality intact, still profitable for holders
Author pushes back on rejection of buyout offers, confirming IOVA remains an acquisition target and that shareholders will still profit; implies continued upside from M&A optionality despite any rejection narrative.
MED
01:19
Aug 25
Aug 25
Short IOVA: MRNA/MRK shrink TAM
Short IOVA because MRNA/MRK adjuvant melanoma therapy prevents post-resection recurrence, directly shrinking the addressable market for IOVA's unresectable melanoma treatments.
MED
03:09
Aug 24
Aug 24
IOVA discussion, no directional view expressed.
Author criticizes another user's inaccurate IOVA posts but does not state a bullish or bearish position on the stock itself.
LOW
02:28
Aug 24
Aug 24
Adjuvant PD1/mRNA vaccines shrink IOVA TAM
Adjuvant PD-1 and likely mRNA vaccines may shrink Iovance total addressable market for TIL therapy; bearish thesis but no explicit short or puts.
MED
23:17
Aug 23
Aug 23
IOVA TAM reduced but squeeze was technical
Author says MRNA news is legitimately bad for IOVA, directly reduces TAM, and made IOVA slightly less valuable; bearish view without explicit short.
LOW
23:00
Aug 23
Aug 23
IOVA dip seen as opportunity with M&A premium.
Frames IOVA dip as a buying opportunity, anticipating short-squeeze volatility, eventual rebound to $6-7, and inevitable M&A at a premium despite concerns about data quality.
MED
22:44
Aug 23
Aug 23
IOVA rally on MRNA squeeze called non-fundamental
Author says the MRNA short squeeze is a mild fundamental negative and objectively bad news for IOVA, with the stock rally making no fundamental sense; bearish view without explicit short.
MED
22:42
Aug 23
Aug 23
Author states a mild to moderately bearish view and calls IOVA a commercial disaster so far.
Author states a mild to moderately bearish view and calls IOVA a commercial disaster so far, while hoping for a turnaround; bearish view without explicit short.
LOW
22:31
Aug 23
Aug 23
Author argues that preventative approaches from MRK/MRNA would reduce Iovance's addressable.
Author argues that preventative approaches from MRK/MRNA would reduce Iovance's addressable market, a competitive analysis rather than a trade position.
LOW
20:54
Aug 23
Aug 23
IOVA top conviction on Amtagvi cure data
Buy IOVA because Amtagvi/lifileucel shows a possible 30% durable/cure response in metastatic melanoma after one treatment, with expansion trials in NSCLC, endometrial carcinoma, sarcoma, and breast cancer supporting long-term upside.
MED
20:38
Aug 23
Aug 23
IOVA guidance revision priced in after surge
Author discusses IOVA management's hyped guidance revision expectations and questions the marketing approach, noting any upside revision is priced in after the stock's >100% move.
LOW
19:27
Aug 23
Aug 23
Adjuvant treatments shrink IOVA treatment population.
Short IOVA because adjuvant therapies that prevent recurrent metastatic disease directly shrink the addressable patient population for Iovance’s treatment, undermining long-term demand.
MED
18:07
Aug 23
Aug 23
Author argues IOVA's recent squeezes are not repeatable and one catalyst worsened fundamentals.
Author argues IOVA's recent squeezes are not repeatable and one catalyst worsened fundamentals, but stops short of a short call.
LOW
17:39
Aug 23
Aug 23
Short IOVA: losses persist, competitors to erode share
Short IOVA on structural competitive deterioration: persistent nine-figure annual losses, upcoming market share loss to MRK/MRNA and REPL regimens with lower toxicity, shrinking melanoma patient pool, and a $4B valuation unjustified by fundamentals; recent rally is squeeze-driven, not fundamental.
MED
14:46
Aug 21
Aug 21
Author clarifies he publicly closed a prior trade to buy more ABCL and IOVA.
Author clarifies he publicly closed a prior trade to buy more ABCL and IOVA, but does not state current positions or forward direction.
LOW
20:52
Aug 20
Aug 20
IOVA flagged as relative strength candidate
Author flags IOVA in a reply about relative strength while XBI is down; no directional thesis or mechanism beyond the ticker mention.
LOW
20:34
Aug 20
Aug 20
Author short IOVA on position call.
Short IOVA following the author's explicit short positioning; the tweet is a positioning call rather than a catalyst-driven thesis, so the actionable edge is the bearish stance itself.
MED
19:36
Aug 20
Aug 20
IOVA named as MRNA-damaged short-squeeze name.
In reply, names IOVA as the biotech matching the described MRNA-damaged fundamentals and short-squeeze price action; no position stated.
LOW
19:25
Aug 20
Aug 20
Rerating expected as TIL therapy proves effective.
Author maintains a large spot position, expecting continued rerating as its TIL therapy proves effective and competitors lag in commercialization.
MED
14:34
Aug 20
Aug 20
Author explicitly states they took big positions in IOVA, BB, and LPTH instead of crypto.
Author explicitly states they took big positions in IOVA, BB, and LPTH instead of crypto, expressing satisfaction with equities over missed crypto gains.
12:08
Aug 20
Aug 20
IOVA phase 3 data due at ESMO
IOVA has an upcoming catalyst: initial Phase 3 TIL data for NSCLC expected at ESMO within 60 days; speaker offers no directional view.
LOW
About IOVA Analyst Coverage
Buzzberg tracks IOVA (Iovance Biotherapeutics, Inc.) across 6 sources. 35 bullish vs 2 bearish calls from 8 analysts. Sentiment: predominantly bullish (43%). 77 total trade ideas tracked. Past 7 days: 3 bullish, 2 watch. Latest voices: CryptoCondom, A May MD, seedy19tron.